Evidence map›Paper›PMID 31203459›Full record

ReviewCurrent treatment options in cardiovascular medicine2019

Cardiotoxicities of Modern Treatments in Breast Cancer.

Susan Dent, Chiara Melloni, Josee Ivars, Sarah Sammons, Gretchen Kimmick

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in cardiovascular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Susan DentDuke Cancer Institute, Duke University, DUMC Box 3446, Durham, NC, 27710, USA. susan.dent@duke.edu.
Chiara MelloniDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Josee IvarsFaculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
Sarah SammonsDuke Cancer Institute, Duke University, DUMC Box 3893 Building, Durham, NC, 27710, USA.
Gretchen KimmickDuke Cancer Institute, Duke University, DUMC Box 3204, Durham, NC, 27710, USA.
Duke University · USClinical Research Institute · USDuke Medical Center · USMcMaster University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis paper will focus on novel breast cancer therapies used in clinical practice today, as well as review our understanding of standard therapies and their potential impact on cardiovascular health. RECENT

findingsEstablished and novel treatments such as anthracyclines, HER2-targeted agents, and immunotherapy have contributed to improvements in breast cancer outcomes; however, these treatments may be associated with an increased risk of cardiovascular injury. The number of available breast cancer treatments continues to expand, as does the need for health care providers to understand the potential impact of these treatments on cardiovascular health. Collaborative approaches in the development of risk stratification, prevention, and surveillance strategies for patients exposed to established and novel breast cancer treatments will facilitate improvements in patient outcomes without compromising their cardiovascular health.

Indexed as

Breast cancerCardiac injuryNovel treatments

Identifiers

PMID31203459
OpenAlexW2951333583

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.